WAVEMAN · COMPANY

BWMN · Bowman Consulting Group Ltd.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

BWMN

Name: Bowman Consulting Group Ltd. (BWMN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Bowman Consulting Group Ltd.

PHARMA & BIOTECH · SERVICES-MANAGEMENT CONSULTING SERVICES · CIK 0001847590

FORM 144 · 2☆ WATCH

INSIDER NET · 180D

-$954.9K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+14.9%

XBRL, annual

NET MARGIN

2.6%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$954.9K over 180 days

-$62.3K over 90 days · -$614.2K of it by a 10%+ holder

below 60% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

79 funds added or opened last quarter

more than 57% of Pharma & Biotech

REVENUE

+14.9% year over year

more than 64% of Pharma & Biotech

MARGIN

2.6% net margin

more than 71% of Pharma & Biotech

BUYBACKS

$12.2M repurchased, FY to 2026-06-30

below 68% of Pharma & Biotech

SHORT

4.8% of shares outstanding short · 5.1 days to cover · settled 2026-07-31

more than 52% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$954.9K across 5 people in 180 days.

79 funds added or opened positions in the latest 13F quarter, of 137 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +1.0%

+1.0%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $954.9K sold by insiders over 180 days, 79 funds added last quarter, $62.4K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Bowman Consulting Group Ltd. insiders sold a net $954.9K of stock across 156 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Mulroy Patricia

Director

SELL

2026-08-10

883.0

$37.4K

Swayze Daniel

Chief Operating Officer

SELL

2026-08-07

914.0

$24.9K

Grebbien Virginia Lee

Director

SELL

2026-06-02

7,500.0

$237.4K

Vicks Raymond Jr.

Director

SELL

2026-05-12

1,230.0

$41.0K

Bowman Gary

Chief Executive Officer

SELL

2026-04-22

12,500.0

$383.9K

156 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 151 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

2,399,322.0 sh

$70.1M

BlackRock, Inc.

1,065,510.0 sh

$31.1M

VANGUARD CAPITAL MANAGEMENT LLC

634,836.0 sh

$18.5M

Swedbank AB

430,000.0 sh

$12.6M

DIMENSIONAL FUND ADVISORS LP

409,019.0 sh

$11.9M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Mulroy Patricia

FILED 2026-08-10

$37.4K

Swayze Daniel

FILED 2026-08-07

$25.0K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Buffalo Early Stage Growth Fund

$1.1M POSITION · AS OF 2026-03-31

1.8%

Columbia Integrated Small Cap Growth Fund

$352.8K POSITION · AS OF 2026-02-28

1.2%

GRANDEUR PEAK GLOBAL MICROCAP FUND

$448.6K POSITION · AS OF 2026-04-30

1.0%

Dunham Small Cap Value Fund

$841.1K POSITION · AS OF 2026-04-30

0.9%

Royce Capital Fund - Micro-Cap Portfolio

$492.8K POSITION · AS OF 2026-03-31

0.5%

Royce Micro-Cap Fund

$1.5M POSITION · AS OF 2026-03-31

0.5%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$490.0M	$426.6M	$346.3M	$261.7M
OPERATING INCOME	$19.7M	$-2.0M	$-656.0K	$5.1M
NET INCOME	$12.8M	$3.0M	$-6.6M	$5.0M
EPS (DILUTED)	0.73	0.17	-0.53	0.37
OPERATING CASH FLOW	$35.8M	$24.3M	$11.7M	$9.2M
CASH	$11.1M	$6.7M	$20.7M	$13.3M
LONG-TERM DEBT	$57.6M	$38.1M	$28.8M	$27.2M
BUYBACKS	$18.8M	$23.3M	$745.0K	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE